Nuvation Bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) announced that CEO David Hung, M.D., and CFO Philippe Sauvage will participate in multiple investor conferences in May 2026, including Bank of America, H.C. Wainwright BioConnect, RBC Capital Markets, and TD Cowen oncology summit.
Live webcasts will be available on the company's Investor Relations website, with archived recordings posted for 90 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – NUVB
In the May 6 session, NUVB gained 4.35%, reflecting a moderate positive market reaction. Argus tracked a peak move of +23.4% during that session. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Bank of America Securities 2026 Healthcare Conference – fireside chat on Wednesday, May 13, 2026, at 8:00 a.m. PT in
Las Vegas, NV
- H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ – fireside chat on Tuesday, May 19, 2026, at 1:30 p.m. ET in
New York, NY
- 2026 RBC Capital Markets Global Healthcare Conference – fireside chat on Wednesday, May 20, 2026, at 9:00 a.m. ET in
New York, NY
- TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA – virtual fireside chat on Tuesday, May 26, 2026, at 12:00 p.m. ET
Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-participate-in-upcoming-investor-conferences-302763192.html
SOURCE Nuvation Bio Inc.